Author

H. Kleanthous

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Bioengineering· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Organism:non-human primate· 4 Organism:mouse· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

B. Pulendran· 3 shared D. B. Volkin· 3 shared K. Kaur· 3 shared N. P. King· 3 shared P. S. Arunachalam· 3 shared S. B. Joshi· 3 shared S. Bajoria· 3 shared A. C. Walls· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. Pulendran

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor binding domain (RBD)

O. S. Kumru, S. Bajoria, K. Kaur, J. M. Hickey, G. Van Slyke, J. Doering, K. Berman, C. Richardson, H. Lien, H. Kleanthous, N. J. Mantis, S. B. Joshi, D. B. Volkin

This paper evaluates the stability and immunogenicity of a SARS-CoV-2 RBD VLP vaccine candidate formulated with different adjuvants and finds that AP and AH adjuvants provide comparable immunogenicity to AV, with AP showing higher neutralizing titers.

bioRxiv · Jul 10, 2023Immunology

Enhanced protective efficacy of a novel, thermostable, RBD-S2 fusion immunogen against SARS-CoV-2 and its variants

N. Mittal, S. Kumar, R. S. Rajmani, R. Singh, C. Lemoine, V. Jakob, S. BJ, N. Jagannath, M. Bhat, D. Chakraborty, S. Pandey, A. Jory, S. S. S.A., H. Kleanthous, P. Dubois, , R. Varadarajan

This study evaluates a novel RBD-S2 fusion immunogen that shows enhanced protection against SARS-CoV-2 and its variants in animal models.

bioRxiv · Mar 19, 2023Biophysics

Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2

Y. Feng, M. Yuan, J. M. Powers, M. Hu, J. E. Munt, P. S. Arunachalam, S. R. Leist, L. Bellusci, L. E. Adams, S. Sundaramurthy, L. M. Shirreff, M. L. Mallory, T. D. Scooby, A. Moreno, D. T. OHagan, , B. Pulendran

This study identifies potent pan-sarbecovirus neutralizing antibodies from vaccinated macaques, showing broad neutralization against SARS-CoV-2 variants and related viruses.

bioRxiv · Jan 19, 2023 · PreprintImmunology

Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants

S. A. Rodriguez-Aponte, N. C. Dalvie, T. Y. Wong, R. S. Johnston, C. A. Naranjo, S. Bajoria, O. S. Kumru, K. Kaur, B. P. Russ, K. S. Lee, H. A. Cyphert, M. Barbier, H. D. Rao, M. P. Rajurkar, R. R. Lothe, , J. C. Love

bioRxiv · Sep 14, 2022Bioengineering

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine

P. S. Arunachalam, Y. Feng, U. Ashraf, M. Hu, V. V. Edara, V. I. Zarnitsyna, P. P. Aye, N. Golden, K. W. M. Green, B. M. Threeton, N. J. Maness, B. J. Beddingfield, R. P. Bohm, J. Dufour, K. Russell-Lodrigue, , B. Pulendran

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

bioRxiv · Mar 18, 2022 · PreprintImmunology

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates

N. C. Dalvie, L. H. Tostanoski, S. A. Rodriguez-Aponte, K. Kaur, S. Bajoria, O. Kumru, A. J. Martinot, A. Chandrashekar, K. McMahan, N. B. Mercado, J. Yu, A. Chang, V. M. Giffin, F. Nampanya, S. Patel, , D. H. Barouch

This paper describes a protein subunit vaccine candidate produced in yeast that protects non-human primates against SARS-CoV-2, showing high neutralizing antibody titers and reduced viral loads after challenge.

bioRxiv · Jul 13, 2021 · PreprintImmunology

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

A. C. Walls, M. C. Miranda, M. N. Pham, A. Schaefer, A. Greaney, P. S. Arunachalam, M.-J. Navarro, M. A. Tortorici, K. Rogers, M. A. O'Connor, L. Shireff, D. E. Ferrell, N. Brunette, E. Kepl, J. E. Bowen, , Veesler

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

bioRxiv · Mar 15, 2021Immunology